Proposed preclinical stages for Alzheimer’s disease predict well who is most likely to progress to Alzheimer’s dementia.
What’s better for future treatment of Parkinson’s: patient-derived or banked iPSCs? In comparison, patient’s own come out on top.
A new RNA interference therapy for amyotrophic lateral sclerosis has some success in mice and monkeys.
In the first study of its kind, researchers found a surprisingly low incidence of Lewy body dementias in a U.S. population.
The Alzheimer’s Disease Neuroimaging Initiative has released whole genome sequences from 809 study volunteers.
Interested in Parkinson's? Apply for access to data and tissue samples, and funds to study them, from the Michael J. Fox Foundation.
By tracking Alzheimer’s research funding internationally, a new database could help sponsors coordinate research efforts.
People who carry the Huntington’s gene develop progressively abnormal brain metabolism a decade or more before diagnosis.
Clinical trials could prove the value of amyloid scans to health insurers.
An inhibitor of a cellular stress response prevents neurodegeneration in mice infected with prion protein, and might have potential in other neurodegenerative diseases.
A cancer drug-turned-Alzheimer’s prospect now appears to have potential against a third disease, reportedly protecting animal models from Parkinson’s damage.
The receptor tyrosine kinase ErbB4 could be the latest gene for amyotrophic lateral sclerosis.
Silencing aberrant C9ORF72 mRNA helps normalize pathology in neurons, suggesting the transcripts are toxic to the cells.
Among cognitively healthy older adults, the rate of change in cerebrospinal fluid biomarkers helps predict who will develop Alzheimer’s disease.
Deep brain stimulation restores walking and swimming abilities in rats with spinal injuries, so long as a few nerve fibers remain intact.
No filters selected